Clinical trials: EMG Syndrome

Primary Immunodeficiency

ASIS for GAMMAGARD in Primary Immunodeficiency

• Unknown status
• Age: 21 to 65 years
• Phase 1/2
• Injection or infusion

ASIS Corporation (ASIS) has developed the only automatic injection system for delivery of injectable products to it's optimum/right spot, just outside of the fascia, which exists subdermally (between the skin and muscle).

Trial name

ASISinPI (NCT02123615)

Testing

Gadolinium For abdomen, Gadolinium For lower back, Efficacy of Gammagard subcutaneously at Week 12

Where

United States

Volunteers

60 people, healthy volunteers welcome

Sponsor

ASIS Corporation